Testicular Cancer

Detailed Overview

Testicular cancer is the most common solid malignancy affecting young men aged 15-35. It typically presents as a painless, solid testicular mass. The disease is characterized by predictable lymphatic spread to the retroperitoneal lymph nodes, followed by hematogenous spread to the lungs. The advent of Cisplatin-based combination chemotherapy in the 1970s transformed testicular cancer from a highly fatal disease to a model of curable oncology, boasting a 10-year survival rate exceeding 95%. Management involves a combination of radical surgery, chemotherapy, and sometimes retroperitoneal lymph node dissection (RPLND).

Epidemiology & Demographics

Accounts for 1% of male cancers but is the most common cancer in males aged 15-35. Incidence is ~6 per 100,000 men. Highest rates are in white men of Northern European descent. Rare in African American men.

Etiological Mechanism

The exact cause is unknown, but it is strongly associated with developmental abnormalities in utero. The precursor lesion for almost all GCTs is Germ Cell Neoplasia In Situ (GCNIS), linked to a failure of primordial germ cells to mature properly. Isochromosome 12p [i(12p)] is a pathognomonic genetic alteration found in almost all invasive GCTs.

Primary Causes

Germ Cell Neoplasia In Situ (GCNIS)

Genetic mutations (Isochromosome 12p)

• Cryptorchidism: Undescended testicle increases the risk 4-10 fold. Risk remains elevated even after orchiopexy (surgical correction).
• Personal or Family History: A previous GCT in the contralateral testicle confers a 5% lifetime risk. First-degree relatives also have elevated risk.
• Klinefelter Syndrome: 47,XXY karyotype specifically increases the risk of mediastinal extra-gonadal germ cell tumors.

GCTs arise from GCNIS, which lays dormant until puberty when hormonal changes trigger rapid proliferation and progression to invasive cancer. Seminomas remain localized to the testis longer and spread slowly via lymphatics to the retroperitoneum. They are exceptionally sensitive to radiation and chemotherapy. Non-seminomas are more aggressive, invade blood vessels early, and frequently present with metastatic disease to the lungs, liver, or brain. Choriocarcinoma variants aggressively secrete Human Chorionic Gonadotropin (hCG) and have a very high propensity for early, massive hemorrhagic brain metastases.

Characteristic Clinical Presentation

• Painless Testicular Mass: A firm, solid, non-tender lump in the testicle noticed by the patient or partner.
• Scrotal Heaviness: A dull ache or feeling of heaviness in the lower abdomen, perianal area, or scrotum.
• Back Pain: Signifies metastatic spread to the retroperitoneal lymph nodes causing nerve root compression.

Physical Examination Signs

• Solid Intratesticular Mass
• Gynecomastia

• Infertility: Resulting from the cancer itself, orchiectomy, or gonadotoxic chemotherapy.
• Secondary Malignancies: Increased risk of leukemia or secondary solid tumors decades later due to Etoposide and Cisplatin exposure.

Diagnostic Criteria & Guidelines

Initial diagnosis via high-frequency scrotal ultrasound. Definitive tissue diagnosis and initial treatment is established simultaneously via Radical Inguinal Orchiectomy. *Never* perform a trans-scrotal biopsy, as it seeds the scrotum and alters lymphatic drainage.

Differential Diagnosis

• Epididymo-orchitis (painful, febrile)
• Hydrocele (transilluminates)
• Testicular Torsion (acute severe pain)

Laboratory Tests & Biomarkers

• Alpha-Fetoprotein (AFP): Elevated only in Non-Seminomas (specifically yolk sac or embryonal). NEVER elevated in pure seminoma.
• Beta-hCG: Elevated in 100% of choriocarcinomas, 50% of embryonal carcinomas, and 15% of seminomas.
• Lactate Dehydrogenase (LDH): A non-specific marker of tumor burden and rapid tissue turnover.

Imaging Modalities & Findings

• Scrotal Ultrasound:
• CT Abdomen/Pelvis and Chest:

• Stage I
  Tumor is confined entirely to the testicle and spermatic cord. Negative tumor markers post-orchiectomy.
• Stage II
  Spread to regional (retroperitoneal/para-aortic) lymph nodes.
• Stage III
  Spread beyond retroperitoneal nodes, most commonly to lungs (supradiaphragmatic nodes, visceral organs).

Second-Line & Adjunctive Therapy

For Stage II/III or High-Risk Disease: Bleomycin, Etoposide, and Cisplatin (BEP) chemotherapy for 3-4 cycles. Residual masses post-chemotherapy in non-seminomas require surgical resection (Post-chemo RPLND).

Surgical & Procedural Management

Radical Inguinal Orchiectomy: The testicle and entire spermatic cord are removed through an incision in the groin (not the scrotum). RPLND: Major abdominal surgery to remove all lymph tissue surrounding the aorta and IVC.

Recommended Lifestyle Changes

• Perform monthly Testicular Self-Exams (TSE) starting at puberty.
• Sperm cryopreservation (sperm banking) is strictly recommended BEFORE orchiectomy and chemotherapy.

Patient Counseling & Advice

Reassure the patient of the extremely high cure rate. Heavily emphasize the absolute necessity of rigorous follow-up (frequent CT scans and blood work) for surveillance protocols, as relapses are highly curable if caught early.

Follow-Up & Monitoring Schedule

Intensive surveillance for 5 years: History/physical, tumor markers (AFP, hCG, LDH) every 2-3 months, and CT scans every 4-6 months initially, spacing out over time.

Preventive Strategies

No primary prevention exists. Surgical correction of cryptorchidism before age 1 facilitates easier examination but does not completely eliminate cancer risk.

Excellent. Overall 5-year survival is >95%. Even for 'poor-prognosis' metastatic non-seminoma, cure rates remain around 50-70%.